Conbercept is the first independently developed anti-VEGF drug in China, a novel receptor fusion protein, which was approved by ChinaNational Medical Products Administration in 2013 for the treatment of exudative AMD. This evidence concerns the gene VEGFA and age-related macular degeneration.